USRE48652E1 - Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation - Google Patents

Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation Download PDF

Info

Publication number
USRE48652E1
USRE48652E1 US15/978,986 US200715978986A USRE48652E US RE48652 E1 USRE48652 E1 US RE48652E1 US 200715978986 A US200715978986 A US 200715978986A US RE48652 E USRE48652 E US RE48652E
Authority
US
United States
Prior art keywords
lactobacillus
lactobacillus gasseri
bnr17
gasseri bnr17
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/978,986
Inventor
Ji Hee Kang
Byeung Il You
Sung Il Yun
Han Oh Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioneer Corp
Original Assignee
Bioneer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer Corp filed Critical Bioneer Corp
Priority to US15/978,986 priority Critical patent/USRE48652E1/en
Application granted granted Critical
Publication of USRE48652E1 publication Critical patent/USRE48652E1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • C12R1/225—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/145—Gasseri
    • A23Y2220/37—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a probiotic lactic acid bacterium, more specifically a novel lactic acid bacterium belonging to Lactobacillus sp. isolated from human mother's milk and having excellent probiotic activity such as acid resistance, bile acid resistance and antimicrobial activity and inhibitory activity against body weight augmentation.
  • a lactic acid bacterium shares a long history with human, which is the microorganism that is very profitable for human health and thus in the increasing demand. According to the recent progress of the lactic acid bacterium studies, its applicability has been broadened from general foods to health food and medicines.
  • a lactic acid bacterium is exemplified by Streptococcus sp., Pediococcus sp., Leuconostoc sp., Lactobacillus sp., Sporolactobacillus sp. and Bifidobacterium sp. microorganisms.
  • the lactic acid bacteria have also been used for stimulation of animal growth, improvement of feed utilization, enhancement of resistance against disease, inhibition of the growth of pathogenic bacteria, reduction of mortality, inhibition of the generation of toxic substances and production of various vitamins.
  • lactic acid bacteria have to be the one that is able to adhere directly onto the mucous membrane of the intestine, has to be less destroyed by gastric acid when it is orally administered, has to have strong resistance against bile acid and has to have strong antimicrobial activity against pathogens.
  • lactic acid bacteria When lactic acid bacteria are used for food or medicine for human health, they are supposed to be isolated from human for better effect. In particular, the lactic acid bacteria isolated from mother's milk have been acknowledged to be more effective and safer. However, the human originated lactic acid bacteria have been mostly isolated from adult's feces or breast-feeded infant's feces. The lactic acid bacteria isolated from mother's milk are mostly Lactobacillus reuteri and other lactic acid bacteria have hardly been reported.
  • obesity is a chronic disease whose cause has not been exactly disclosed but whose development is believed to be attributed to the co-work of several different factors.
  • Obesity might cause hypertension, diabetes, cardiovascular disease, galstone, osteoarthritis, sleep spnea syndrome, breathing disorder, prostatic cancer, breast cancer, colon cancer, etc.
  • the conventional methods hired for the prevention and treatment of obesity are largely diet-exercise therapy, surgical operation, drug therapy, etc.
  • the diet-exercise therapy is to encourage taking low-calorie-low fat food and physical exercise to consume oxygen. This method requires patience since it has to be carried out repeatedly and persistently and that is why this method seems to be ineffective for the general public.
  • the surgical operation is to eliminate body fat by surgery. This method has an advantage of obtaining the desired results in a short time but at the same time has disadvantages of painful surgery, doubt of the continuance of the effect and high costs.
  • the drug therapy needs careful attention because it carries many side effects.
  • the present invention relates to a lactic acid bacterium isolated from human mother's milk, and it is an object of the present invention to provide a lactic acid bacterium that has strong resistance against acid, pH and bile acid and strong adherence to intestines so as to convert low-molecular carbohydrates decomposed by a digestive enzyme into high-molecular polysaccharides and to excrete the polysaccharides instead of letting it be absorbed in the body.
  • the present invention provides a Lactobacillus gasseri BNR17 strain, the lactic acid bacterium isolated from human mother's milk.
  • the lactic acid bacteria strain of the present invention has following characteristics.
  • Morphology morphology after culture at 37° C. for 24 hours on the Lactobacilli MRS agar plate medium:
  • Type rod type (Bacillus).
  • Optimum growth temperature 37 ⁇ 40° C.
  • Bile acid resistance survived at 0.3% of bile acid.
  • Adherence to intestines adhered to Caco-2 cells, the human intestinal epithelial cells.
  • Antibiotic resistance resistant to Gentamycin, Kanamycin, Streptomycin, Bacitracin, Neomycin, Nalidixic acid, Ciprofloxacin, Polymixcin B and Trimethoprim.
  • Antimicrobial activity to pathogenic bacteria antimicrobial activity to E. coli, S. aureus, S. typhimurium, B. cereus, L. monocytogenes, and P. mirabilis.
  • Presence of antimicrobial peptide The gene corresponding to gassericin T of bacteriocin, one of antimicrobial peptide components of lactic acid bacteria, is detected by PCR.
  • the lactic acid bacterium of the present invention produces approximately 520 mg/L of polysaccharides after 24 hours of culture on the MRS medium supplemented with 2% glucose.
  • the polysaccharides were composed mainly of glucose, mannose, galactose, fucose, arabinose and D-glucosamine.
  • the polysaccharides produced by the lactic acid bacterium of the present invention are not decomposed by digestive enzymes such as ⁇ -amylase and pancreatine.
  • Koreans have different diet habit with westerners. So, it is clear and natural that the lactic acid bacterium isolated from Koreans have different dietary habits with westerners. So, it is clear and natural that the lactic acid bacterium isolated from Korean best fits to Korean.
  • the lactic acid bacterium isolated from Korean mother's milk fulfills every required fundamental condition for probiotic lactic acid bacterium, resulting in the best health enhancing effect for Korean.
  • lactic acid bacterium having the above characteristics as “Lactobacillus gasseri BNR17” and deposited at Korean Collection for Type Cultures (KCTC) of Korea Research Institute of Biotechnology and Bioscience (KRIBB), located at #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea, on Jan. 23, 2006 (Accession No: KCTC 10902BP).
  • the present invention also provides a composition containing an effective dose of the lactic acid bacterium.
  • the composition of the present invention can be provided in the forms of food, food additives, animal feeds and animal feed additives.
  • Lactobacillus gasseri BNR17 (Accession No: KCTC 10902BP) has excellent acid resistance, bile acid resistance and antimicrobial activity, making it an excellent candidate as a seed for the production of various fermented milk products and other fermented foods.
  • the fermented milk products herein can be exemplified by yoghurt, calpis, cheese and butter, and the other fermented foods herein can be exemplified by tofu, soy bean paste, Chungkukjang, jelly and Kimchi, but not always limited thereto.
  • the fermented milk products and fermented foods can be easily produced by the conventional method only with substituting the strain with the lactic acid bacterium of the invention.
  • the lactic acid bacterium food products of the present invention can be produced as an edible form of composition either containing Lactobacillus gasseri BNR17 alone or with any acceptable carrier.
  • the lactic acid bacterium of the invention can be added to the food that does not contain any probiotic bacteria or the food that already contains several kinds of probiotic bacteria.
  • the microorganism that can be co-used with the lactic acid bacterium of the invention to produce the lactic acid bacterium food has to be appropriate for intake by human or animals and have probiotic activity such as inhibiting pathogenic bacteria or improving the balance of microorganisms in the mammal's intestines, but not always limited thereto.
  • the probiotic microorganism is exemplified by yeasts such as Saccharomyces, Candida, Pichia and Torulopsis; fungi such as Aspergillus, Rhizopus, Mucor and Penicillium; and bacteria belonging to Lactobacillus, Bifidobacterium, Leuconostoc, Lactococcus, Bacillus, Streptococcus, Propionibacterium, Enterococcus and Pediococcus.
  • yeasts such as Saccharomyces, Candida, Pichia and Torulopsis
  • fungi such as Aspergillus, Rhizopus, Mucor and Penicillium
  • the probiotic microorganism can be selected from the group consisting of Saccharomyces cerevisiae, Bacillus coagulans, Bacillus licheniformis, Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Enterococcus faecium, Enterococcus faecalis, Lactobacillus acidophilus, Lactobacillus alimentarius, Lactobacillus casei, Lactobacillus curvatus, Lactobacillus delbruckii, Lactobacillus johnsonii, Lactobacillus farciminus, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus sakei, Lactococcus lactis and Pediococcus acidilactici.
  • a carrier acceptable for the lactic acid bacterium food of the invention is exemplified by a diluent, a high-fiber additive, an encapsulant and a lipid, which have been well informed to those skilled in the art.
  • the lactic acid bacterium of the invention Lactobacillus gasseri BNR17, can be formulated as capsules, culture suspension or dried powder.
  • composition containing the lactic acid bacterium of the invention can be prepared as animal feeds or animal feed additives.
  • the animal feed additive of the invention can be prepared in dried or liquid form and can contain other non-pathogenic microorganisms in addition to the Lactobacillus gasseri BNR17.
  • the addable microorganism can be selected from the group consisting of Bacillus subtilis producing protease, lipase and sugar converting enzyme; lactobacillus strain having organic decomposition activity and maintaining physical activities under anaerobic condition; filamentous fungi such as Aspergillus oryzae (Slyter, L. L. J. Animal Sci. 1976, 43. 910-926) contributing to the increase of milk and weight of cattle and feed digestibility as well; and yeast such as Saccharomyces cerevisiae (Johnson, D. E et al. J. Anim. Sci., 1983, 56, 735-739; Williams, P. E. V. et al, 1990, 211).
  • the animal feed additive of the present invention can additionally include one or more enzyme products in addition to the Lactobacillus gasseri BNR17.
  • the addable enzyme product can be in dried or liquid form, which is selected from the group consisting of lipase, phytase decomposing phytic acid into phosphate and inositol phosphate, amylase hydrolyzing ⁇ -1,4-glycoside bond included in starch and glycogen, phosphatase hydrolyzing organic phosphoric acid ester, carboxymethylcellulase decomposing cellulose, xylase decomposing xylose, maltase hydrolyzing maltose into two glucoses and invertase hydrolyzing saccharose into glucose-fructose.
  • the proper feed raw material is selected from the group consisting of crops, soybean protein, peanut, green pea, sugar beet, pulp, crop byproduct, animal intestine powder and fish powder. At this time, these materials can be used as they are or after being processed.
  • raw material for feed is compressed by pressure to be discharged, but not always limited thereto.
  • extrusion is preferred. Particularly, extrusion is to denaturate a protein by heat-treatment, resulting in the destruction of anti-enzyme factors.
  • extrusion improves the digestibility of the protein, inactivates anti-nutrition factors such as trypsin inhibitor, one of protease inhibitors, and increases digestibility by a protease, resulting in the increase of nutritional value of the protein.
  • the present invention further provides a pharmaceutical composition for the prevention and treatment of obesity which contains the effective dose of Lactobacillus gasseri BNR17 (Accession No: KCTC 10902BP).
  • the Lactobacillus gasseri BNR17 of the invention is generally administered as a tablet or a capsule prepared by mixing the lactic acid bacterium with a pharmaceutically acceptable carrier, an excipient or another effective supplementary component.
  • the acceptable carrier, excipient or diluent for the pharmaceutical composition of the invention is exemplified by lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, tragacanth gum, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil.
  • the microorganism composition of the invention can additionally include lubricants, wetting agents, emulsifying agents, suspension agents, preserving agents, sweetening agents or flavors.
  • composition of the invention can be prepared in the form of enteric coated preparation in order for the composition to pass through the stomach and reach the small intestine safely and to release microorganism, the active ingredient, therein fast and easy, according to the conventional method well known to those skilled in the art.
  • the microorganism composition of the present invention can also be prepared in the form of a capsule, according to the conventional capsule production method.
  • a standard carrier is used for the preparation of a pellet containing the freezing-dried microorganism of the invention, which fills soft gelatin capsules.
  • the microorganism of the invention is mixed with a pharmaceutically acceptable carrier, for example soluble gum, cellulose, silicate or oil, to prepare suspension or dispersing solution, which fills soft gelatin capsules.
  • the pharmaceutical composition of the present invention can be provided as a unit drug form for oral administration as an enteric coated preparation.
  • Enteric coating herein indicates that a drug is not decomposed by gastric acid and maintained as being coated but is decomposed in the small intestine to release active ingredients therein, which includes every kind of pharmaceutically acceptable coatings.
  • “Enteric coating” of the invention is maintained at least two hours in the artificial gastric juice such as HCl solution (pH 1) at 36-38° C. but the coating is preferably decomposed within 30 minutes in the artificial intestinal juice such as KH 2 PO 4 buffer solution (pH 6.8).
  • Enteric coating of the invention is performed, in which one core is coated by 16-30 mg, preferably 16-20 mg or less than mg of the composition.
  • the preferable thickness of the coating is 5-100 ⁇ m and more preferably 20-80 ⁇ m for the best results.
  • Materials for the enteric coating can be selected among the well-informed high molecular substances. Those high molecular substances are described in numbers of references (L. Lachman, et al., The Theory and Practice of Industrial Pharmacy, 3 rd edition, 1986, pp. 365 ⁇ 373; H. Sucker, et al., Pharmazeutician Technologie, Thieme, 1991, pp. 355-359; Hagers Handbuch der pharmazeutician fürtechnik, 4 th edition, Vol. 7, pp.
  • the enteric coating of the invention can be performed by the conventional method which is spraying the coating solution onto a core.
  • the acceptable solvent for the enteric coating is selected from the group consisting of alcohol such as ethanol, ketone such as acetone, halogenized hydrocarbon such as CH 2 Cl 2 and a mixture thereof.
  • a softener such as di-n-butylphthalate or triacetine can be added to the coating solution at the ratio of 1:0.05-0.3 (coating material:softener). It is preferred to spray serially and the amount of spry is determined by considering the coating conditions. Spraying pressure can be regulated and generally 1-1.5 bar is considered to give best results.
  • the “pharmaceutically effective dosage” of the invention indicates the minimum amount of the microorganism of the invention that is able to reduce low-sugar carbohydrates to be absorbed into the intestines of mammals.
  • the dosage of the microorganism, which is delivered to the human body by the composition of the invention, can be regulated according to the administration pathway and subjects.
  • the composition of the invention can be administered to a subject at least once a day, everyday.
  • Unit dosage indicates the unit separated physically to be appropriate for unit administration to a subject, either human or other mammals, and each unit contains a required amount of acceptable carrier and a required amount of the microorganism of the invention for the treatment effect.
  • the unit dosage for oral administration of the composition of the invention is preferably 0.1-10 g and more preferably 0.5-5 g.
  • the pharmaceutically effective dosage of the microorganism of the invention is 0.1-10 g/day. However, the dosage might vary according to the weight of a patient, the severity of obesity, and effective supplementary ingredients and microorganisms.
  • the one day dosage can be divided into several sub-units so that they can be administered serially if necessary. Thus, the dosage of the composition of the invention cannot limit the spirit and scope of the invention in any way.
  • the regular administration of the composition of the invention results in the interruption of the absorption of saccharides inside the human body by releasing microorganisms to compete and form microflora, which interrupts the absorption, and further involves in the convert of monosaccharides such as carbohydrate into polysaccharides so as to inhibit the absorption thereof.
  • dietary fiber produced by the microorganism provides preferable conditions for useful enterobacteria to grow with stimulating intestinal motility. Therefore, the composition of the invention can be effectively used for the prevention and treatment of obesity.
  • any weight reducing agent known to those skilled in the art can be additionally included in the composition by a proper amount.
  • the amount can be determined by those skilled in the art after multiple tests.
  • the effective ingredient as an additive, the weight reducing agent is preferably selected from the group consisting of conjugated linoleic acid, polydextrose, inulin, guar gum, arabic gum, L-carteine, grape seed extract, fructooligosaccharide, xylooligosaccharide, raffinose, gluconic acid, champignon, polyanthocyanidine, lactulose, lactitol, lactosucrose, Angelica gigas extract, Hovenia dulcis extract and tangerine peel extract, but not always limited thereto.
  • the present invention also provides a culture solution prepared by culturing Lactobacillus gasseri BNR17 (Accession No: KCTC 10902BP).
  • the medium used to prepare the culture solution is not limited, and any medium that contains a medium for microorganism culture can be used.
  • the culture solution of the invention can additionally contain any additive if necessary for a specific use. For example, to maximize the weight reducing effect, any weight reducing agent well known to those skilled in the art can be added to the culture solution and at this time the content of the agent can be determined by those skilled in the art after examining the effective dose range through repeated tests.
  • the present invention also provides a bacteriocin peptide produced by the lactic acid bacterium of the invention and a gene encoding the same.
  • the present inventors named the bacteriocin peptide as “gassericin BNR17” which was confirmed to have the nucleotide sequence represented by SEQ. ID. NO: 5.
  • the nucleotide sequence of the gassericin BNR17 was compared with that of the conventional antimicrobial peptide, gassericin T (NCBI Blast Search No. AB029612, SEQ. ID. NO: 6), and as a result, the gassericin BNR17 had approximately 98% homology with the gassericin T.
  • the present invention further provides a recombinant vector containing the gassericin BNR17 gene.
  • the recombinant vector of the present invention can be prepared by inserting the gene having the nucleotide sequence represented by SEQ. ID. NO: 5 into a general expression vector for E. coli.
  • the mother vector for the construction of the recombinant vector is not limited to a specific one, and almost every microorganism expression vector can be used but an E. coli expression vector is preferred.
  • the present invention also provides a transformant transformed with the recombinant vector.
  • the transformant of the invention can be easily generated by introducing the above recombinant vector into a random host cell.
  • the host cell herein can be selected from the group consisting of eukaryotic or prokaryotic cells and multicellular animal originated cell lines, but not always limited thereto.
  • FIG. 1 is a diagram showing the sequence comparison between Lactobacillus gasseri BNR17 of the invention (upper sequence in figure, SEQ. ID. NO: 1) and Lactobacillus gasseri KC26 (NCBI GENBANK Accession No: AF243156, lower sequence in figure, SEQ. ID. NO: 2) 16s rRNAs.
  • FIG. 2 is a microphotograph showing the enteric adherence of Lactobacillus gasseri BNR17 of the invention.
  • FIG. 3 is a set of photographs showing that Lactobacillus gasseri BNR17 of the invention has antimicrobial activity against various pathogenic bacteria.
  • FIG. 4 is a graph showing the glucose consumption and polysaccharide production according to the growth of Lactobacillus gasseri BNR17 of the invention.
  • FIG. 5 is a graph showing the amount of feces of a rat taking Lactobacillus gasseri BNR17 of the invention.
  • FIG. 6 is a graph showing the EPS (polysaccharide) concentration in the feces of a rat taking Lactobacillus gasseri BNR17 of the invention.
  • FIG. 7 is a set of electrophoresis photographs showing the RAPD-PCR profiles of colonies isolated from other organs than the small intestine of a rat taking Lactobacillus gasseri BNR17 of the invention, in which primers represented by SEQ. ID. NO: 7 (A), NO: 8 (B) and NO: 9 (C) were used.
  • the colonies were cultured in MRS medium (pH 2.0) for 2 hours, followed by further culture in MRS medium supplemented with 0.3% oxgall for 9 hours.
  • the survived lactobacillus strain that exhibited acid resistance and bile acid resistance was isolated and identified by 16S rRNA sequencing. As a result, the strain was confirmed to belong Lactobacillus gasseri species (SEQ. ID. NO: 1, FIG. 1 ) and named as “Lactobacillus gasseri BNR17”.
  • Lactobacillus gasseri BNR17 of the invention isolated above was investigated by comparing with other standard strains using API50CHL kit (Biomerieux, France) and the results are shown in Table 1.
  • Table 1 5314 indicates Lactobacillus gasseri CECT5714; 5315 indicates Lactobacillus gasseri CECT5715; 11413 indicates Lactobacillus gasseri LMG11413; 18194 indicates Lactobacillus gasseri LMG18194; 4479 indicates Lactobacillus gasseri CECT4479; 18176 indicates Lactobacillus gasseri LMG 18176; and 13047 indicates Lactobacillus gasseri LMG13047.
  • Lactobacillus gasseri BNR17 of the invention was distinguishable in sugar utilization from others (shown in thick Italics).
  • Example 2 The enzyme activity of the Lactobacillus gasseri BNR17 isolated in Example 1 was compared with those of other standard strains using APIZYM kit (Biomerieux, France) and the results are shown in Table 2.
  • 13134 indicates Lactobacillus gasseri LMG13134.
  • Lactobacillus gasseri BNR17 of the invention was distinguishable in enzyme activity from other strains (shown in thick Italics).
  • Lactobacillus gasseri BNR17 was inoculated in 4 ml of MRS liquid medium and cultured at 37° C. for 18-20 hours. Some of the culture solution was reinoculated in another MRS medium with regulated pH of 2.0 at the concentration of 10 7 CFU/ml and cultured at 37° C. for 2 hours. The number of live cells was counted using MRS agar plate. The culture solution tested for acid resistance was used again for centrifugation. The cells were recovered and inoculated in MRS liquid medium (pH 6.8) supplemented with 0.3% oxgall, followed by culture at 37° C. for 9 hours. The number of live cells was also counted using MRS agar plate. The results are shown in Table 3.
  • Lactobacillus gasseri BNR17 exhibited high survival rate, and so did in the medium supplemented with 0.3% oxgall.
  • the strain of the invention was inoculated on the plate on which a human intestinal epithelial cell line CaCo-2 was cultured in PRMI1640 (Gibco) at the concentration of 10 7 CFU/ml.
  • the strain was cultured at 37° C. for one hour, followed by washing three times with PBS to eliminate non-adhered cells.
  • the sample was fixed with methanol and then stained with crystal violet, followed by observation under a microscope.
  • the Lactobacillus gasseri BNR17 of the invention was confirmed to be very well adhered on CaCo-2 cells ( FIG. 2 ).
  • E. coli, S. aureus, S. typhimurium, B. cereus, L. monocytogenes and P. mirabilis were cultured at 37° C. for 18 hours in BHI liquid medium (Difco) and then inoculated in 6 of 5 ml BHI agar media (agar content: 0.7%) respectively at the concentration of 10 5 CFU/ml. These media were overlapped on 6 plates with BHI agar media (agar content: 1.5%) fixed thereon. After hardening those 6 plate media, a well of 4 mm in diameter was made in each medium, in which 40 ⁇ l of the supernatant (2 ⁇ ) of lactic acid bacterium culture solution cultured at 37° C. for 24 was added, followed by culture at 37° C. for 5 hours.
  • Lactobacillus gasseri BNR17 culture solution was smeared on MRS agar plate by using a swab, on which a disc containing erythromycin, penicillin, gentamycin, kanamycin, streptomycin, bacitracin, chloramphenicol, vancomycin, tetracycline, ampicillin, cefoxitin, rifampin, neomycin, nalidixic acid, ciprofloxacin, polymixcin B or trimethoprim was placed, followed by culture at 37° C. for 24 hours.
  • Lactobacillus gasseri BNR17 of the invention was confirmed to have resistance against gentamycin, streptomycin and trimethoprim.
  • Bacteriocin gene was investigated by PCR performed by using the Lactobacillus gasseri BNR17 genomic DNA as a template and primers represented by SEQ. ID. NO: 3 and NO: 4 which were specific to the nucleotide sequence of a gene of bacteriocin known as an antimicrobial peptide produced by Lactobacillus gasseri species.
  • the PCR product corresponding to gassericin was confirmed and represented by SEQ. ID. NO: 5.
  • the nucleotide sequence was compared with that of gassericin T (NCBI Blast Search No. AB029612) represented by SEQ. ID. NO: 6 and confirmed to have approximately 98% homology.
  • ⁇ -glucuronidase produced by enterobacteria has been known as one of oncogenic enzymes and thus the strain that has this enzyme activity is considered as a harmful strain.
  • the enzyme activity of Lactobacillus gasseri BNR17 was tested using API ZYM kit (Biomerieux, France).
  • Lactobacillus gasseri BNR17 was inoculated in MRS medium (Difco) prepared by adding 2% glucose (w/v) at the concentration of 10 6 cfu/ml and cultured for 96 hours, during which the cell number was measured stepwise and at the same time glucose consumption and extracellular polysaccharide (EPS) production were measured as well.
  • MRS medium Difco
  • EPS extracellular polysaccharide
  • Lactobacillus gasseri BNR17 was observed on the 12 th hour of culture and since then the level had been decreased.
  • Glucose concentration was rapidly reduced after 7 hours of culture and no changes of glucose concentration were detected after 36 hours, suggesting that most of glucose was consumed within 36 hours from the culture started.
  • EPS production was maximized on the 24 th hour (the highest level: 520 mg/k) and was slightly reduced on the 36 th hour but increased again thereafter. It was presumed to be attributed to autolysis of the cells causing various polysaccharides in the cells to be released into the culture solution ( FIG. 4 ).
  • each number indicates organ weight (g)/rat weight (g).
  • RAPD-PCR profiles of colonies of each organ tissue cultured on LBS agar plate were investigated by using primers p1, p2 and OPL5 respectively represented by SEQ. ID. NO: 7-NO: 9.
  • PCR using the primers p1 and p2 was performed as follows; 94° C. (2 minutes), 36° C. (5 minutes), 72° C. (5 minutes)—4 cycles/94° C. (1 minute), 36° C. (1 minute), 72° C. (2 minutes)—36 cycles.
  • PCR using the primer OPL5 was performed as follows; 94° C. (2 minutes)—1 cycle/94° C. (40 seconds), 45° C. (1 minute), 72° C. (1 minute)—2 cycles/94° C. (40 seconds), 52° C. (1 minute), 72° C. (3 minutes)—30 cycles/70° C. (5 minutes)—1 cycle.
  • BNR17 was confirmed to be safe strain which is not transferred to other organs except the small intestine when it is taken.
  • Raw milk in which milk solid non fat content was regulated by 8-20% using powdered skim milk was sterilized at 72-75° C. for 15 seconds.
  • the sterilized raw milk was cooled down to the proper temperature, to which Lactobacillus gasseri BNR17 of the invention was inoculated at the concentration of 10 6 cfu/ml, followed by culture until pH reached 4-5.
  • the culture solution was cooled down.
  • 0.1-50 weight % of fruit juice concentrate, 0.1-20 weight % of dietary fiber, 0.5-30 weight % of glucose, 0.1-15 weight % of oligosaccharide, 0.01-10 weight % of calcium and 0.001-5 weight % of vitamin were all dissolved to prepare syrup.
  • the syrup was sterilized, cooled down, and mixed with the above culture solution, followed by stirring for homogenization.
  • the resultant mixture was packed, resulting in the preparation of fermented milk. Flavor, physical property, and taste of the fermented milk product were tested, and the results were satisfactory.
  • Lactobacillus gasseri BNR17 of the invention was inoculated into MRS liquid medium at the concentration of 10 6 cfu/ml, followed by pH-control fermentation at 37° C. for 18-24 hours. pH-control was performed by using 30 volume % NaOH as a neutralizing agent to pH 5.7 ⁇ 0.2. Upon completion of the culture, centrifugation was performed at 4° C. with 10,000 ⁇ g to recover cells. A protectant supplemented with 5 weight % of skim milk, 2.5 weight % of whey, and 5 weight % of sucrose (for the total weight of the composition) was prepared. Equal amounts of the recovered cells and the protectant were mixed, followed by pulverization by using a freeze dryer.
  • the produced Lactobacillus gasseri BNR17 dried powder contained over 1 ⁇ 10 11 cfu/g live cells.
  • the protectant can additionally include 10 weight % of trehalose, 10 weight % of maltodextrine and 7.5 weight % of lactose.
  • Lactic acid bacteria products such as lactic acid bacteria foods and digestives were prepared from the lactic acid bacteria powder produced in Manufacturing Example 2.
  • 10 weight % of oligosaccharide, 20 weight % of anhydrous glucose, 5 weight % of crystalline fructose, 2 weight % of vitamin C, 5 weight % of fruit powder flavor, 5 weight % of aloe, 15 weight % of dietary fiber, and 18 weight % of Psyllium Husk were added to 20 weight % of Lactobacillus gasseri BNR17 dried powder, and the mixture was packed in sticks or bottles.
  • the live cells in the lactic acid bacteria product prepared thereby were more than 5 ⁇ 10 8 cfu/g.
  • a composition for feed additive containing Lactobacillus gasseri BNR17 was prepared by the following compositions shown in Table 9.
  • the enzyme preparation used herein was a mixture of phytase, cellulase, xylase, maltase and invertase, and the non-pathogenic microorganism was Aspergillus oryzae.
  • the Lactobacillus gasseri BNR17 of the invention has wide growth temperature and pH ranges allowed. And, the strain of the invention not only has excellent acid resistance, bile acid resistance and enteric adsorption capacity but also strong antimicrobial activity against pathogenic microorganisms, in addition to weight gaining inhibitory effect. Therefore, the strain of the invention can be effectively used for the production of fermented milk and other fermented products and be very useful as an additive for animal feed as well.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)

Abstract

The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body. Therefore, the strain of the invention, owing to such beneficiary effects, can be effectively used not only for the production of fermented milk, other fermented food products and animal feeds but also for the production of live cell products and food additives for preventing weight gaining.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is a Reissue application of U.S. Pat. No. 8,309,076 and Continuation Reissue application of U.S. application Ser. No. 14/537,565, filed Nov. 10, 2014 (issued as U.S. Pat. No. RE16,912 on Jun. 26, 2018), which is a Reissue application of U.S. Pat. No. 8,309,076 issued on Nov. 13, 2012, which is issued from the 35 U.S.C. §371 National Phase Entry Application from PCT/KR2007/002363, filed May 14, 2007, and designating the United States, which claims priority under 35 U.S.C. § 119 to Korean Patent Application No. 10-2006-0073722 filed Aug. 4, 2006, which is incorporated herein in its entirety.
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
The present invention relates to a probiotic lactic acid bacterium, more specifically a novel lactic acid bacterium belonging to Lactobacillus sp. isolated from human mother's milk and having excellent probiotic activity such as acid resistance, bile acid resistance and antimicrobial activity and inhibitory activity against body weight augmentation.
DESCRIPTION OF THE RELATED ART
A lactic acid bacterium shares a long history with human, which is the microorganism that is very profitable for human health and thus in the increasing demand. According to the recent progress of the lactic acid bacterium studies, its applicability has been broadened from general foods to health food and medicines. A lactic acid bacterium is exemplified by Streptococcus sp., Pediococcus sp., Leuconostoc sp., Lactobacillus sp., Sporolactobacillus sp. and Bifidobacterium sp. microorganisms.
Lactic acid bacteria inhabit in the animal's intestines where they decompose nutrients and cellulose that the host animal has taken and then use them as an energy source to produce lactic acid and antibiotics in order to inhibit the growth of pathogenic bacteria in the intestine to keep the intestine healthy. The lactic acid bacteria have also been used for stimulation of animal growth, improvement of feed utilization, enhancement of resistance against disease, inhibition of the growth of pathogenic bacteria, reduction of mortality, inhibition of the generation of toxic substances and production of various vitamins.
However, to be effective in the intestine, the incoming lactic acid bacteria from outside have to arrive to the intestines safe and be attached onto the mucous membrane to be functioning. To do so, lactic acid bacteria have to be the one that is able to adhere directly onto the mucous membrane of the intestine, has to be less destroyed by gastric acid when it is orally administered, has to have strong resistance against bile acid and has to have strong antimicrobial activity against pathogens.
When lactic acid bacteria are used for food or medicine for human health, they are supposed to be isolated from human for better effect. In particular, the lactic acid bacteria isolated from mother's milk have been acknowledged to be more effective and safer. However, the human originated lactic acid bacteria have been mostly isolated from adult's feces or breast-feeded infant's feces. The lactic acid bacteria isolated from mother's milk are mostly Lactobacillus reuteri and other lactic acid bacteria have hardly been reported.
Meanwhile, obesity is a chronic disease whose cause has not been exactly disclosed but whose development is believed to be attributed to the co-work of several different factors. Obesity might cause hypertension, diabetes, cardiovascular disease, galstone, osteoarthritis, sleep spnea syndrome, breathing disorder, prostatic cancer, breast cancer, colon cancer, etc. The conventional methods hired for the prevention and treatment of obesity are largely diet-exercise therapy, surgical operation, drug therapy, etc. The diet-exercise therapy is to encourage taking low-calorie-low fat food and physical exercise to consume oxygen. This method requires patience since it has to be carried out repeatedly and persistently and that is why this method seems to be ineffective for the general public. The surgical operation is to eliminate body fat by surgery. This method has an advantage of obtaining the desired results in a short time but at the same time has disadvantages of painful surgery, doubt of the continuance of the effect and high costs. The drug therapy needs careful attention because it carries many side effects.
Recently, studies on polysaccharides produced by lactic acid bacteria have been actively undergoing. The mechanism that lactic acid bacteria produce extracellular polysaccharides is known to be very complicated. There are huge differences in productivity and the structure of the polysaccharides according to the kinds of lactic acid bacteria. Polysaccharides produced by lactic acid bacteria have been reported to have anticancer activity and immune enhancing activity (Kitazawa, H. Int. J. Food Microbiol., 1998. 40. 169-175, Hosono, A. Biosci. Biotechnol. Biochem., 1997. 61. 312-316, Chabot, S. Lait. 2001. 81. 683-697). It is also expected to be very safe to take the polysaccharides produced by lactic acid bacteria because lactic acid bacteria themselves are classified as GRAS (Generally Recognized As Safe).
SUMMARY OF THE INVENTION
The present invention relates to a lactic acid bacterium isolated from human mother's milk, and it is an object of the present invention to provide a lactic acid bacterium that has strong resistance against acid, pH and bile acid and strong adherence to intestines so as to convert low-molecular carbohydrates decomposed by a digestive enzyme into high-molecular polysaccharides and to excrete the polysaccharides instead of letting it be absorbed in the body.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
To achieve the above object, the present invention provides a Lactobacillus gasseri BNR17 strain, the lactic acid bacterium isolated from human mother's milk.
The lactic acid bacteria strain of the present invention has following characteristics.
{circle around (1)} Morphology—morphology after culture at 37° C. for 24 hours on the Lactobacilli MRS agar plate medium:
i. Shape, size and color of colony: round, 0.5 mm×2 mm, milk-white color, smooth surface.
ii. Gram staining: positive.
iii. Type: rod type (Bacillus).
iv. Sporulation: no.
v. Mobility: no.
{circle around (2)} Physiological properties
i. Growth temperature: 25˜45° C.
ii. Growth pH: pH 4.0˜10.0
iii. Optimum growth temperature: 37˜40° C.
iv. Optimum growth pH: pH 6.0˜8.0
{circle around (3)} Influence of oxygen: facultative anaerobic.
{circle around (4)} Sugar availability:
Glycerol −, Ribose −, Adonitol −, Galactose +, D-Glucose +, D-Fructose +, D-Mannose +, Mannitol −, Sorbitol −, N-Acetylglucoside +, Esculin +, Salicin +, Cellobiose +, Maltose +, Lactose +, Melibiose −, Saccharose +, Trehalose +, Inulin −, Melezitose −, Raffinose −, Starch −, β-Gentiobiose −, D-Turanose +, D-Tagatose +
{circle around (5)} Acid resistance: survived at pH 2.0.
{circle around (6)} Bile acid resistance: survived at 0.3% of bile acid.
{circle around (7)} Adherence to intestines: adhered to Caco-2 cells, the human intestinal epithelial cells.
{circle around (8)} Antibiotic resistance: resistant to Gentamycin, Kanamycin, Streptomycin, Bacitracin, Neomycin, Nalidixic acid, Ciprofloxacin, Polymixcin B and Trimethoprim.
sensitive to Erythromycin, Penicillin, Tetracycline, Ampicillin, Chloramphenicol, Vancomycin and Cefoxitin, Rifampin.
{circle around (9)} Antimicrobial activity to pathogenic bacteria: antimicrobial activity to E. coli, S. aureus, S. typhimurium, B. cereus, L. monocytogenes, and P. mirabilis.
{circle around (10)} Presence of antimicrobial peptide: The gene corresponding to gassericin T of bacteriocin, one of antimicrobial peptide components of lactic acid bacteria, is detected by PCR.
{circle around (11)} Polysaccharide generation: The lactic acid bacterium of the present invention produces approximately 520 mg/L of polysaccharides after 24 hours of culture on the MRS medium supplemented with 2% glucose. The polysaccharides were composed mainly of glucose, mannose, galactose, fucose, arabinose and D-glucosamine. The polysaccharides produced by the lactic acid bacterium of the present invention are not decomposed by digestive enzymes such as α-amylase and pancreatine.
Koreans have different diet habit with westerners. So, it is clear and natural that the lactic acid bacterium isolated from Koreans have different dietary habits with westerners. So, it is clear and natural that the lactic acid bacterium isolated from Korean best fits to Korean. The lactic acid bacterium isolated from Korean mother's milk fulfills every required fundamental condition for probiotic lactic acid bacterium, resulting in the best health enhancing effect for Korean. The present inventors named such lactic acid bacterium having the above characteristics as “Lactobacillus gasseri BNR17” and deposited at Korean Collection for Type Cultures (KCTC) of Korea Research Institute of Biotechnology and Bioscience (KRIBB), located at #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea, on Jan. 23, 2006 (Accession No: KCTC 10902BP).
The present invention also provides a composition containing an effective dose of the lactic acid bacterium. The composition of the present invention can be provided in the forms of food, food additives, animal feeds and animal feed additives.
The novel lactic acid bacterium provided by the invention, Lactobacillus gasseri BNR17 (Accession No: KCTC 10902BP) has excellent acid resistance, bile acid resistance and antimicrobial activity, making it an excellent candidate as a seed for the production of various fermented milk products and other fermented foods. The fermented milk products herein can be exemplified by yoghurt, calpis, cheese and butter, and the other fermented foods herein can be exemplified by tofu, soy bean paste, Chungkukjang, jelly and Kimchi, but not always limited thereto. The fermented milk products and fermented foods can be easily produced by the conventional method only with substituting the strain with the lactic acid bacterium of the invention.
According to a preferred embodiment of the present invention, approximately 7.7% weight gaining inhibitory effect was observed in the experimental group rats administered with Lactobacillus gasseri BNR17, compared with the control group rats administered with PBS (phosphate-buffered saline)(see Table 6). In addition to the weight gaining inhibitory effect, diet efficiency in the experimental group was also reduced significantly, compared with the control group. Polysaccharides included in feces of both experimental and control groups were examined. As a result, the polysaccharide content in feces of experimental group was higher than that of control group (see FIG. 6). These results indicate that the indigestible polysaccharide producing capacity of Lactobacillus gasseri BNR17 plays a certain role in weight regulation. In the meantime, no superficial side effects have been detected in the experimental group rats taking Lactobacillus gasseri BNR17 and the weight of each organ was not much different from that of control group (see Table 7 and Table 8). Microorganism transition, one of major concerns when human takes a microorganism, was not observed, suggesting that the lactic acid bacterium of the present invention is very safe for human to take (see FIG. 7).
The lactic acid bacterium food products of the present invention can be produced as an edible form of composition either containing Lactobacillus gasseri BNR17 alone or with any acceptable carrier. The lactic acid bacterium of the invention can be added to the food that does not contain any probiotic bacteria or the food that already contains several kinds of probiotic bacteria. The microorganism that can be co-used with the lactic acid bacterium of the invention to produce the lactic acid bacterium food has to be appropriate for intake by human or animals and have probiotic activity such as inhibiting pathogenic bacteria or improving the balance of microorganisms in the mammal's intestines, but not always limited thereto. The probiotic microorganism is exemplified by yeasts such as Saccharomyces, Candida, Pichia and Torulopsis; fungi such as Aspergillus, Rhizopus, Mucor and Penicillium; and bacteria belonging to Lactobacillus, Bifidobacterium, Leuconostoc, Lactococcus, Bacillus, Streptococcus, Propionibacterium, Enterococcus and Pediococcus. Preferably, the probiotic microorganism can be selected from the group consisting of Saccharomyces cerevisiae, Bacillus coagulans, Bacillus licheniformis, Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Enterococcus faecium, Enterococcus faecalis, Lactobacillus acidophilus, Lactobacillus alimentarius, Lactobacillus casei, Lactobacillus curvatus, Lactobacillus delbruckii, Lactobacillus johnsonii, Lactobacillus farciminus, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus sakei, Lactococcus lactis and Pediococcus acidilactici. It is more preferred to add a probiotic microorganism mixture having excellent probiotic activity and immune enhancing activity as well as anticancer activity to the lactic acid bacterium food of the invention, resulting in greater effect. A carrier acceptable for the lactic acid bacterium food of the invention is exemplified by a diluent, a high-fiber additive, an encapsulant and a lipid, which have been well informed to those skilled in the art. The lactic acid bacterium of the invention, Lactobacillus gasseri BNR17, can be formulated as capsules, culture suspension or dried powder.
In addition, the composition containing the lactic acid bacterium of the invention can be prepared as animal feeds or animal feed additives.
The animal feed additive of the invention can be prepared in dried or liquid form and can contain other non-pathogenic microorganisms in addition to the Lactobacillus gasseri BNR17. The addable microorganism can be selected from the group consisting of Bacillus subtilis producing protease, lipase and sugar converting enzyme; lactobacillus strain having organic decomposition activity and maintaining physical activities under anaerobic condition; filamentous fungi such as Aspergillus oryzae (Slyter, L. L. J. Animal Sci. 1976, 43. 910-926) contributing to the increase of milk and weight of cattle and feed digestibility as well; and yeast such as Saccharomyces cerevisiae (Johnson, D. E et al. J. Anim. Sci., 1983, 56, 735-739; Williams, P. E. V. et al, 1990, 211).
The animal feed additive of the present invention can additionally include one or more enzyme products in addition to the Lactobacillus gasseri BNR17. The addable enzyme product can be in dried or liquid form, which is selected from the group consisting of lipase, phytase decomposing phytic acid into phosphate and inositol phosphate, amylase hydrolyzing α-1,4-glycoside bond included in starch and glycogen, phosphatase hydrolyzing organic phosphoric acid ester, carboxymethylcellulase decomposing cellulose, xylase decomposing xylose, maltase hydrolyzing maltose into two glucoses and invertase hydrolyzing saccharose into glucose-fructose.
When the lactic acid bacterium of the invention is added to the animal feed as an additive, the proper feed raw material is selected from the group consisting of crops, soybean protein, peanut, green pea, sugar beet, pulp, crop byproduct, animal intestine powder and fish powder. At this time, these materials can be used as they are or after being processed. To process the animal feed, for example, raw material for feed is compressed by pressure to be discharged, but not always limited thereto. In the case of using a protein as a raw material, extrusion is preferred. Particularly, extrusion is to denaturate a protein by heat-treatment, resulting in the destruction of anti-enzyme factors. More specifically, in the case of using a soybean protein, extrusion improves the digestibility of the protein, inactivates anti-nutrition factors such as trypsin inhibitor, one of protease inhibitors, and increases digestibility by a protease, resulting in the increase of nutritional value of the protein.
The present invention further provides a pharmaceutical composition for the prevention and treatment of obesity which contains the effective dose of Lactobacillus gasseri BNR17 (Accession No: KCTC 10902BP).
The Lactobacillus gasseri BNR17 of the invention is generally administered as a tablet or a capsule prepared by mixing the lactic acid bacterium with a pharmaceutically acceptable carrier, an excipient or another effective supplementary component.
The acceptable carrier, excipient or diluent for the pharmaceutical composition of the invention is exemplified by lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, tragacanth gum, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil. The microorganism composition of the invention can additionally include lubricants, wetting agents, emulsifying agents, suspension agents, preserving agents, sweetening agents or flavors. The composition of the invention can be prepared in the form of enteric coated preparation in order for the composition to pass through the stomach and reach the small intestine safely and to release microorganism, the active ingredient, therein fast and easy, according to the conventional method well known to those skilled in the art.
The microorganism composition of the present invention can also be prepared in the form of a capsule, according to the conventional capsule production method. For example, a standard carrier is used for the preparation of a pellet containing the freezing-dried microorganism of the invention, which fills soft gelatin capsules. Another example is that the microorganism of the invention is mixed with a pharmaceutically acceptable carrier, for example soluble gum, cellulose, silicate or oil, to prepare suspension or dispersing solution, which fills soft gelatin capsules.
The pharmaceutical composition of the present invention can be provided as a unit drug form for oral administration as an enteric coated preparation. “Enteric coating” herein indicates that a drug is not decomposed by gastric acid and maintained as being coated but is decomposed in the small intestine to release active ingredients therein, which includes every kind of pharmaceutically acceptable coatings. “Enteric coating” of the invention is maintained at least two hours in the artificial gastric juice such as HCl solution (pH 1) at 36-38° C. but the coating is preferably decomposed within 30 minutes in the artificial intestinal juice such as KH2PO4 buffer solution (pH 6.8).
Enteric coating of the invention is performed, in which one core is coated by 16-30 mg, preferably 16-20 mg or less than mg of the composition. The preferable thickness of the coating is 5-100 μm and more preferably 20-80 μm for the best results. Materials for the enteric coating can be selected among the well-informed high molecular substances. Those high molecular substances are described in numbers of references (L. Lachman, et al., The Theory and Practice of Industrial Pharmacy, 3rd edition, 1986, pp. 365˜373; H. Sucker, et al., Pharmazeutische Technologie, Thieme, 1991, pp. 355-359; Hagers Handbuch der pharmazeutischen Praxis, 4th edition, Vol. 7, pp. 739-742, and 766-778, (SpringerVerlag, 1971); and Remington's Pharmaceutical Sciences, 13th edition, pp. 1689˜1691 (Mack Publ., Co., 1970)), which can be exemplified by cellulose ester derivatives, cellulose ether, methylacrylate copolymer of acrylic resin and copolymer of maleic acid and phthalic acid derivatives.
The enteric coating of the invention can be performed by the conventional method which is spraying the coating solution onto a core. The acceptable solvent for the enteric coating is selected from the group consisting of alcohol such as ethanol, ketone such as acetone, halogenized hydrocarbon such as CH2Cl2 and a mixture thereof. A softener such as di-n-butylphthalate or triacetine can be added to the coating solution at the ratio of 1:0.05-0.3 (coating material:softener). It is preferred to spray serially and the amount of spry is determined by considering the coating conditions. Spraying pressure can be regulated and generally 1-1.5 bar is considered to give best results.
The “pharmaceutically effective dosage” of the invention indicates the minimum amount of the microorganism of the invention that is able to reduce low-sugar carbohydrates to be absorbed into the intestines of mammals. The dosage of the microorganism, which is delivered to the human body by the composition of the invention, can be regulated according to the administration pathway and subjects.
The composition of the invention can be administered to a subject at least once a day, everyday. Unit dosage indicates the unit separated physically to be appropriate for unit administration to a subject, either human or other mammals, and each unit contains a required amount of acceptable carrier and a required amount of the microorganism of the invention for the treatment effect. The unit dosage for oral administration of the composition of the invention is preferably 0.1-10 g and more preferably 0.5-5 g. The pharmaceutically effective dosage of the microorganism of the invention is 0.1-10 g/day. However, the dosage might vary according to the weight of a patient, the severity of obesity, and effective supplementary ingredients and microorganisms. The one day dosage can be divided into several sub-units so that they can be administered serially if necessary. Thus, the dosage of the composition of the invention cannot limit the spirit and scope of the invention in any way.
The regular administration of the composition of the invention results in the interruption of the absorption of saccharides inside the human body by releasing microorganisms to compete and form microflora, which interrupts the absorption, and further involves in the convert of monosaccharides such as carbohydrate into polysaccharides so as to inhibit the absorption thereof. In addition, dietary fiber produced by the microorganism provides preferable conditions for useful enterobacteria to grow with stimulating intestinal motility. Therefore, the composition of the invention can be effectively used for the prevention and treatment of obesity.
To maximize the weight reducing effect or obesity preventive effect of the pharmaceutical composition, any weight reducing agent known to those skilled in the art can be additionally included in the composition by a proper amount. The amount can be determined by those skilled in the art after multiple tests. The effective ingredient as an additive, the weight reducing agent, is preferably selected from the group consisting of conjugated linoleic acid, polydextrose, inulin, guar gum, arabic gum, L-carteine, grape seed extract, fructooligosaccharide, xylooligosaccharide, raffinose, gluconic acid, champignon, polyanthocyanidine, lactulose, lactitol, lactosucrose, Angelica gigas extract, Hovenia dulcis extract and tangerine peel extract, but not always limited thereto.
The present invention also provides a culture solution prepared by culturing Lactobacillus gasseri BNR17 (Accession No: KCTC 10902BP). The medium used to prepare the culture solution is not limited, and any medium that contains a medium for microorganism culture can be used. The culture solution of the invention can additionally contain any additive if necessary for a specific use. For example, to maximize the weight reducing effect, any weight reducing agent well known to those skilled in the art can be added to the culture solution and at this time the content of the agent can be determined by those skilled in the art after examining the effective dose range through repeated tests.
The present invention also provides a bacteriocin peptide produced by the lactic acid bacterium of the invention and a gene encoding the same. The present inventors named the bacteriocin peptide as “gassericin BNR17” which was confirmed to have the nucleotide sequence represented by SEQ. ID. NO: 5. The nucleotide sequence of the gassericin BNR17 was compared with that of the conventional antimicrobial peptide, gassericin T (NCBI Blast Search No. AB029612, SEQ. ID. NO: 6), and as a result, the gassericin BNR17 had approximately 98% homology with the gassericin T.
The present invention further provides a recombinant vector containing the gassericin BNR17 gene.
The recombinant vector of the present invention can be prepared by inserting the gene having the nucleotide sequence represented by SEQ. ID. NO: 5 into a general expression vector for E. coli. The mother vector for the construction of the recombinant vector is not limited to a specific one, and almost every microorganism expression vector can be used but an E. coli expression vector is preferred.
The present invention also provides a transformant transformed with the recombinant vector.
The transformant of the invention can be easily generated by introducing the above recombinant vector into a random host cell. The host cell herein can be selected from the group consisting of eukaryotic or prokaryotic cells and multicellular animal originated cell lines, but not always limited thereto.
BRIEF DESCRIPTION OF THE DRAWINGS
The application of the preferred embodiments of the present invention is best understood with reference to the accompanying drawings, wherein:
FIG. 1 is a diagram showing the sequence comparison between Lactobacillus gasseri BNR17 of the invention (upper sequence in figure, SEQ. ID. NO: 1) and Lactobacillus gasseri KC26 (NCBI GENBANK Accession No: AF243156, lower sequence in figure, SEQ. ID. NO: 2) 16s rRNAs.
FIG. 2 is a microphotograph showing the enteric adherence of Lactobacillus gasseri BNR17 of the invention.
FIG. 3 is a set of photographs showing that Lactobacillus gasseri BNR17 of the invention has antimicrobial activity against various pathogenic bacteria.
FIG. 4 is a graph showing the glucose consumption and polysaccharide production according to the growth of Lactobacillus gasseri BNR17 of the invention.
    • Figure USRE048652-20210720-P00001
      ; cell growth, ♦; glucose concentration,
      Figure USRE048652-20210720-P00002
      ; EPS (polysaccharide) concentration
FIG. 5 is a graph showing the amount of feces of a rat taking Lactobacillus gasseri BNR17 of the invention.
FIG. 6 is a graph showing the EPS (polysaccharide) concentration in the feces of a rat taking Lactobacillus gasseri BNR17 of the invention.
FIG. 7 is a set of electrophoresis photographs showing the RAPD-PCR profiles of colonies isolated from other organs than the small intestine of a rat taking Lactobacillus gasseri BNR17 of the invention, in which primers represented by SEQ. ID. NO: 7 (A), NO: 8 (B) and NO: 9 (C) were used.
Lane 1; Lb. gasseri BNR17, Lanes 2-5; colonies isolated from other organs than the small intestine of a rat taking Lb. gasseri BNR17,
M; DNA size marker.
EXAMPLES
Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples.
However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may make modifications and improvements within the spirit and scope of the present invention.
Example 1 Lactic Acid Bacterium Isolation from Human Mother's Milk
Human mother's milk was taken from a woman delivered of a baby not more than two weeks ago. Then, the mother's milk was diluted with PBS and the undiluted milk and diluted milk were distributed on a lactobacillus selection medium respectively. The medium was cultured at 37° C. for 2-3 days and the colonies generated therein were sorted by morphology and color. The isolated colonies were Gram-stained and observed under a microscope to select those colonies that were Gram-positive and had rod-shaped structure. The selected colonies were cultured in MRS liquid medium (pH 6.8) at 37° C. for 24 hours. Colonies in the culture solution under the pH lower than 4.5 were selected. The colonies were cultured in MRS medium (pH 2.0) for 2 hours, followed by further culture in MRS medium supplemented with 0.3% oxgall for 9 hours. The survived lactobacillus strain that exhibited acid resistance and bile acid resistance was isolated and identified by 16S rRNA sequencing. As a result, the strain was confirmed to belong Lactobacillus gasseri species (SEQ. ID. NO: 1, FIG. 1) and named as “Lactobacillus gasseri BNR17”.
Example 2 Sugar Utilization of the Isolated Lactic Acid Bacterium
Sugar utilization of Lactobacillus gasseri BNR17 of the invention isolated above was investigated by comparing with other standard strains using API50CHL kit (Biomerieux, France) and the results are shown in Table 1. In Table 1, 5314 indicates Lactobacillus gasseri CECT5714; 5315 indicates Lactobacillus gasseri CECT5715; 11413 indicates Lactobacillus gasseri LMG11413; 18194 indicates Lactobacillus gasseri LMG18194; 4479 indicates Lactobacillus gasseri CECT4479; 18176 indicates Lactobacillus gasseri LMG 18176; and 13047 indicates Lactobacillus gasseri LMG13047.
TABLE 1
BNR17 5714 5715 11413 18194 4479 18176 13047
Glycerol 0 0 0 0 0 0 0 0
Erythritol 0 0 0 0 0 0 0 0
Figure USRE048652-20210720-P00003
 0 0 4 0 0 0 0 0
Figure USRE048652-20210720-P00004
 0 0 4 0 0 0 0 0
Ribose 0 0 0 0 0 0 0 0
D-Xylose 0 0 0 0 0 0 0 0
L-Xylose 0 0 0 0 0 0 0 0
Adonitol 0 0 0 0 0 0 0 0
β-Methyl- 0 0 0 0 0 0 0 0
xyloside
Galactose
5 5 5 5 5 5 5 5
D-Glucose 5 5 5 5 5 5 5 5
D-Fructose 5 5 5 5 5 5 5 5
D-mannose 5 5 5 5 5 5 5 5
Figure USRE048652-20210720-P00005
 0 0 0 5 0 0 0 0
Rhamnose 0 0 0 0 0 0 0 0
Figure USRE048652-20210720-P00006
 0 0 0 4 0 0 0 0
Inositol 0 0 0 0 0 0 0 0
Figure USRE048652-20210720-P00007
 0 0 3 5 0 0 0 0
Sorbitol 0 0 0 0 0 0 0 0
α-Methyl-D- 0 0 0 0 0 0 0 0
mannoside
α-Methyl-D- 0 0 0 0 0 0 0 0
glucoside
N-Acetlyglu- 5 4 5 5 5 5 5 5
cosamine
Figure USRE048652-20210720-P00008
 5 5 5 0 0 5 5 0
Figure USRE048652-20210720-P00009
 5 5 5 1 1 5 5 4
Esculine 5 5 5 5 5 5 5 5
Salicine 5 5 5 5 5 5 5 3
Cellobiose 5 5 5 5 5 5 5 5
Maltose 5 5 5 5 5 5 5 5
Figure USRE048652-20210720-P00010
 5 0 4 5 5 5 5 0
Figure USRE048652-20210720-P00011
 0 0 0 0 0 0 5 0
Saccharose 5 5 5 5 5 5 5 5
Trehalose 5 5 5 5 5 5 5 5
Inuline 0 0 0 0 0 0 0 0
Melezilose 0 0 0 0 0 0 0 0
D-Raffmose 0 0 0 0 0 0 5 0
Figure USRE048652-20210720-P00012
 5 3 5 1 1 5 3 3
Figure USRE048652-20210720-P00013
 0 0 0 4 4 0 0 0
Xylitol 0 0 0 0 0 0 0 0
b-Gentobiose 5 5 5 5 5 5 5 5
Figure USRE048652-20210720-P00014
 5 0 0 0 0 0 0 0
D-Lycose 0 0 0 0 0 0 0 0
Figure USRE048652-20210720-P00015
 5 5 5 3 3 5 5 5
D-Fucose 0 0 0 0 0 0 0 0
L-Fucose 0 0 0 0 0 0 0 0
D-Arabinol 0 0 0 0 0 0 0 0
As shown in Table 1, compared with other lactobacillus strains, the Lactobacillus gasseri BNR17 of the invention was distinguishable in sugar utilization from others (shown in thick Italics).
Example 3 Enzyme Activity of the Isolated Lactic Acid Bacterium
The enzyme activity of the Lactobacillus gasseri BNR17 isolated in Example 1 was compared with those of other standard strains using APIZYM kit (Biomerieux, France) and the results are shown in Table 2. In Table 2, 13134 indicates Lactobacillus gasseri LMG13134.
TABLE 2
BNR17 11413 13047 13134 18176 18194 4479 5714 5715
Control − − − − − − − − −
Alkaline phosphates − − − − − − − − −
Esterase (C4) 1 2 1 1 1 1 1 1 1
Esterase lipase (C8) − − − 1 − − − − −
Lipase (C4) − − − − − − − − −
Leucine + + + + + + + + +
arylamidase
Figure USRE048652-20210720-P00016
 1 1 1 3 2 − − − 1
Figure USRE048652-20210720-P00017
Figure USRE048652-20210720-P00018
 1 1 1 4 2 3 4 1 1
Figure USRE048652-20210720-P00019
Trypsin − − − − − − − − −
α-chymotrypsin − − 1 − − − − − −
Figure USRE048652-20210720-P00020
 + 1 2 + − 1 2 1 1
Figure USRE048652-20210720-P00021
 + 1 + + + − + + +
Figure USRE048652-20210720-P00022
Figure USRE048652-20210720-P00023
 + + − − + − + + +
Figure USRE048652-20210720-P00024
 + 4 1
Figure USRE048652-20210720-P00025
 − + + − − − − − −
Figure USRE048652-20210720-P00026
 1 1 + − 1 2 1 − 1
Figure USRE048652-20210720-P00027
 3 + + 3 4 +
Figure USRE048652-20210720-P00028
 1 + 1 − + − − − 1
Figure USRE048652-20210720-P00029
α-mannosidase − − − − − − − −
α-fiteesidase − − − − − − − − −
As shown in Table 2, the Lactobacillus gasseri BNR17 of the invention was distinguishable in enzyme activity from other strains (shown in thick Italics).
Example 4 Acid Resistance and Bile Acid Resistance
To investigate acid resistance and bile acid resistance of the strain of the invention, Lactobacillus gasseri BNR17 was inoculated in 4 ml of MRS liquid medium and cultured at 37° C. for 18-20 hours. Some of the culture solution was reinoculated in another MRS medium with regulated pH of 2.0 at the concentration of 107 CFU/ml and cultured at 37° C. for 2 hours. The number of live cells was counted using MRS agar plate. The culture solution tested for acid resistance was used again for centrifugation. The cells were recovered and inoculated in MRS liquid medium (pH 6.8) supplemented with 0.3% oxgall, followed by culture at 37° C. for 9 hours. The number of live cells was also counted using MRS agar plate. The results are shown in Table 3.
TABLE 3
Before Treatment at 0.3% expall
treatment pH 2.0 treatment
BNR17 3.1 × 107 2.1 × 107 1.5 × 107
As a result, even after the treatment with strong acid (pH 2.0), the Lactobacillus gasseri BNR17 exhibited high survival rate, and so did in the medium supplemented with 0.3% oxgall.
Example 5 Enteric Adherence
The strain of the invention was inoculated on the plate on which a human intestinal epithelial cell line CaCo-2 was cultured in PRMI1640 (Gibco) at the concentration of 107 CFU/ml. The strain was cultured at 37° C. for one hour, followed by washing three times with PBS to eliminate non-adhered cells. The sample was fixed with methanol and then stained with crystal violet, followed by observation under a microscope. As a result, the Lactobacillus gasseri BNR17 of the invention was confirmed to be very well adhered on CaCo-2 cells (FIG. 2).
Example 6 Antimicrobial Activity Against Pathogenic Bacteria
E. coli, S. aureus, S. typhimurium, B. cereus, L. monocytogenes and P. mirabilis were cultured at 37° C. for 18 hours in BHI liquid medium (Difco) and then inoculated in 6 of 5 ml BHI agar media (agar content: 0.7%) respectively at the concentration of 105 CFU/ml. These media were overlapped on 6 plates with BHI agar media (agar content: 1.5%) fixed thereon. After hardening those 6 plate media, a well of 4 mm in diameter was made in each medium, in which 40 μl of the supernatant (2×) of lactic acid bacterium culture solution cultured at 37° C. for 24 was added, followed by culture at 37° C. for 5 hours.
As a result, a clear growth inhibition ring was observed around the well, suggesting that the strain of the invention has antimicrobial activity against various pathogenic bacteria (Table 4 and FIG. 3).
TABLE 4
Diameter of growth
Pathogenic bacteria inhibition ring (mm)
E. coli KCTC1039 16
B. cereus KCTC1526 16
L. monocytogenes KCTC3710 12
P mirabilis KCTC2510 14
S. aureus KCTC1928  6
S. typhimurium KCTC2421 18
Example 7 Antibiotic Resistance
Lactobacillus gasseri BNR17 culture solution was smeared on MRS agar plate by using a swab, on which a disc containing erythromycin, penicillin, gentamycin, kanamycin, streptomycin, bacitracin, chloramphenicol, vancomycin, tetracycline, ampicillin, cefoxitin, rifampin, neomycin, nalidixic acid, ciprofloxacin, polymixcin B or trimethoprim was placed, followed by culture at 37° C. for 24 hours.
As a result, Lactobacillus gasseri BNR17 of the invention was confirmed to have resistance against gentamycin, streptomycin and trimethoprim.
Example 8 Detection of the Antimicrobial Peptide Gene
Bacteriocin gene was investigated by PCR performed by using the Lactobacillus gasseri BNR17 genomic DNA as a template and primers represented by SEQ. ID. NO: 3 and NO: 4 which were specific to the nucleotide sequence of a gene of bacteriocin known as an antimicrobial peptide produced by Lactobacillus gasseri species.
As a result, the PCR product corresponding to gassericin was confirmed and represented by SEQ. ID. NO: 5. The nucleotide sequence was compared with that of gassericin T (NCBI Blast Search No. AB029612) represented by SEQ. ID. NO: 6 and confirmed to have approximately 98% homology.
Example 9 β-glucuronidase Activity
β-glucuronidase produced by enterobacteria has been known as one of oncogenic enzymes and thus the strain that has this enzyme activity is considered as a harmful strain. To investigate whether the Lactobacillus gasseri BNR17 of the invention has β-glucuronidase activity or not, the enzyme activity of Lactobacillus gasseri BNR17 was tested using API ZYM kit (Biomerieux, France).
As a result, the strain of the invention was confirmed not to have β-glucuronidase activity, suggesting that the strain was safe (Table 5).
TABLE 5
Enzyme Activity
α-galactosidase Positive
β-galactosidase Positive
β-glucuronidase Negative
α-glucosidase Negative
β-glucosidase Positive
Example 10 Glucose Consumption and Polysaccharide Production
Lactobacillus gasseri BNR17 was inoculated in MRS medium (Difco) prepared by adding 2% glucose (w/v) at the concentration of 106 cfu/ml and cultured for 96 hours, during which the cell number was measured stepwise and at the same time glucose consumption and extracellular polysaccharide (EPS) production were measured as well.
As a result, the highest level of Lactobacillus gasseri BNR17 was observed on the 12th hour of culture and since then the level had been decreased. Glucose concentration was rapidly reduced after 7 hours of culture and no changes of glucose concentration were detected after 36 hours, suggesting that most of glucose was consumed within 36 hours from the culture started. EPS production was maximized on the 24th hour (the highest level: 520 mg/k) and was slightly reduced on the 36th hour but increased again thereafter. It was presumed to be attributed to autolysis of the cells causing various polysaccharides in the cells to be released into the culture solution (FIG. 4).
Example 11 Decomposition of the Polysaccharide Produced by Lactobacillus Gasseri BNR17 by a Digestive Enzyme
100 mg of each α-amylase (Sigma) and pancreatin (Sigma) was dissolved in 0.05 M phosphate buffer (pH 7.0). 50 μl of the above enzyme solution and 150 μl of 0.05 M phosphate buffer (pH 7.0) were added to 200 μl of polysaccharide (EPS) solution extracted from the supernatant of Lactobacillus gasseri BNR17 culture solution, followed by reaction at 37° C. for one hour. The reaction mixture was heated at 100° C. for 15 minutes to inactivate enzymes therein, followed by cooling at room temperature. Glucose concentration was measured with a glucose kit (Sigma).
As a result, glucose was not detected in the polysaccharide solution before the treatment of each digestive enzyme, while 3.70 mg/l and 19.1 mg/l of glucose were respectively detected after the treatment of pancreatin and α-amylase. This result indicates that the polysaccharide produced by Lactobacillus gasseri BNR17 was hardly decomposed by a digestive enzyme.
Example 12 Weight Gaining Inhibitory Effect of Lactobacillus Gasseri BNR17
8 week old male SD rats were grouped into two. One group was orally administered with PBS only (pH 7.4) and the other group was orally administered with PBS suspended with 109 CFU/ml of Lactobacillus gasseri BNR17, everyday for 8 weeks. Changes of weights, food intakes, and blood chemical values such as cholesterol level were measured once a week. The amounts of feces and EPS in feces were also measured to investigate the relation of weight gaining inhibitory effect of Lactobacillus gasseri BNR17 and polysaccharide production capacity thereof. 8 weeks later, all the test animals were sacrificed and dissected to extract the liver, kidney, spleen, MLN (mesenteric lymph node), which were measured their weights. Some of each organ extracted was homogenized and smeared on LBS agar, a lactobacillus selection medium, which was then cultured and RAPD (random amplified polymorphic DNA)-PCR profiles of the generated colonies were investigated. The result was compared with the RAPD-PCR profile of Lactobacillus gasseri BNR17 to investigate whether the strain was transferred to other organs.
As a result, approximately 179.1% weight increase was observed for 8 weeks in the control group orally administered with PBS only, while approximately 171.6% weight increase was observed in the experimental group orally administered with Lactobacillus gasseri BNR17 (Table 6). The experimental group also exhibited lower rates of one-day weight increase and food efficiency ratio than the control.
TABLE 6
Weight Food
Weight (g) gaining efficiency
Group Initial weight Final weight* (g/day) ratio**
Control 221.20 ± 3.759  393.73 ± 4.860  3.081 0.131 ± 0.078
BNR17 223.66 ± 10.077 380.85 ± 21.517 2.807 0.115 ± 0.067
In Table 6, food efficiency ratio (FER) indicates weight gaining (g day)/food intake (g day). *P<0.05, **P<0.05.
The results of measuring the amounts of feces and EPS in feces of both the control and the experimental groups are shown in FIG. 5 and FIG. 6. The amounts of feces were not much different between the control and the experimental groups, but the ESP amount was significantly increased in the experimental group administered with Lactobacillus gasseri BNR17. This result indicates that Lactobacillus gasseri BNR17 converts sugar components taken inside body into indigestible polysaccharides so as to release the polysaccharides out of the body, resulting in the decrease of in vivo absorption rate and inhibition of weight gaining.
To examine safety of the strain for human administration, blood chemical values and organ weights were measured. Each levels and values were similar in the control and the experimental groups, suggesting that the strain did not cause side effects (Table 7 and Table 8).
TABLE 7
Cholesterol Glucose HDL LDL Total protein Triglyceride
Group (mg/dL) (mg/dL) (mg/dL) (mg/dL) (OL) (mg/dL)
Control 99.7 ± 11.7 88.9 ± 12.1 38.5 ± 3.5 21.5 ± 1.6 8.6 ± 0.3 115.9 ± 11.0
BNR17 96.3 ± 6.3  79.2 ± 4. 1 40.8 ± 1.8 20.8 ± 3.1 9.0 ± 0.3 132.6 ± 5.5 
TABLE 8
Group Liver Kidney Spleen
Control 0.029 ± 0.001 0.007 ± 0.000 0.002 ± 0.000
BNR17 0.027 ± 0.003 0.007 ± 0.001 0.002 ± 0.000
In Table 8, each number indicates organ weight (g)/rat weight (g).
To investigate whether the strain was transferred to other organs, RAPD-PCR profiles of colonies of each organ tissue cultured on LBS agar plate were investigated by using primers p1, p2 and OPL5 respectively represented by SEQ. ID. NO: 7-NO: 9. PCR using the primers p1 and p2 was performed as follows; 94° C. (2 minutes), 36° C. (5 minutes), 72° C. (5 minutes)—4 cycles/94° C. (1 minute), 36° C. (1 minute), 72° C. (2 minutes)—36 cycles. PCR using the primer OPL5 was performed as follows; 94° C. (2 minutes)—1 cycle/94° C. (40 seconds), 45° C. (1 minute), 72° C. (1 minute)—2 cycles/94° C. (40 seconds), 52° C. (1 minute), 72° C. (3 minutes)—30 cycles/70° C. (5 minutes)—1 cycle.
As a result, no colonies exhibited similar profiles to BNR17 (FIG. 7). Thus, BNR17 was confirmed to be safe strain which is not transferred to other organs except the small intestine when it is taken.
Manufacturing Example 1 Preparation of Fermented Milk
Raw milk in which milk solid non fat content was regulated by 8-20% using powdered skim milk was sterilized at 72-75° C. for 15 seconds. The sterilized raw milk was cooled down to the proper temperature, to which Lactobacillus gasseri BNR17 of the invention was inoculated at the concentration of 106 cfu/ml, followed by culture until pH reached 4-5. Upon completion of the culture, the culture solution was cooled down. In the meantime, 0.1-50 weight % of fruit juice concentrate, 0.1-20 weight % of dietary fiber, 0.5-30 weight % of glucose, 0.1-15 weight % of oligosaccharide, 0.01-10 weight % of calcium and 0.001-5 weight % of vitamin were all dissolved to prepare syrup. The syrup was sterilized, cooled down, and mixed with the above culture solution, followed by stirring for homogenization. The resultant mixture was packed, resulting in the preparation of fermented milk. Flavor, physical property, and taste of the fermented milk product were tested, and the results were satisfactory.
Manufacturing Example 2 Preparation of Lactic Acid Bacteria Powder
Lactobacillus gasseri BNR17 of the invention was inoculated into MRS liquid medium at the concentration of 106 cfu/ml, followed by pH-control fermentation at 37° C. for 18-24 hours. pH-control was performed by using 30 volume % NaOH as a neutralizing agent to pH 5.7±0.2. Upon completion of the culture, centrifugation was performed at 4° C. with 10,000×g to recover cells. A protectant supplemented with 5 weight % of skim milk, 2.5 weight % of whey, and 5 weight % of sucrose (for the total weight of the composition) was prepared. Equal amounts of the recovered cells and the protectant were mixed, followed by pulverization by using a freeze dryer. The produced Lactobacillus gasseri BNR17 dried powder contained over 1×1011 cfu/g live cells. The protectant can additionally include 10 weight % of trehalose, 10 weight % of maltodextrine and 7.5 weight % of lactose.
Manufacturing Example 3 Preparation of Lactic Acid Bacteria Products
Lactic acid bacteria products such as lactic acid bacteria foods and digestives were prepared from the lactic acid bacteria powder produced in Manufacturing Example 2. 10 weight % of oligosaccharide, 20 weight % of anhydrous glucose, 5 weight % of crystalline fructose, 2 weight % of vitamin C, 5 weight % of fruit powder flavor, 5 weight % of aloe, 15 weight % of dietary fiber, and 18 weight % of Psyllium Husk were added to 20 weight % of Lactobacillus gasseri BNR17 dried powder, and the mixture was packed in sticks or bottles. The live cells in the lactic acid bacteria product prepared thereby were more than 5×108 cfu/g.
Manufacturing Example 4 Preparation of a Composition for Feed Additive
A composition for feed additive containing Lactobacillus gasseri BNR17 was prepared by the following compositions shown in Table 9.
TABLE 9
Component ratio of the composition for feed additive (weight %)
Lacto- Non-
bacillus Enzyme pathogenic
gasseri prepa- micro- Amino
BNR17 ration organism acid Others
Manufacturing 100 — — — —
Example <4-1>
Manufacturing  90 10 — — —
Example <4-2>
Manufacturing  80 10 10 — —
Example <4-3>
Manufacturing  70 10 10 10 —
Example <4-4>
Manufacturing  60 15 15  8 2
Example <4-5>
Manufacturing  50 20 15  8 2
Example <4-6>
The enzyme preparation used herein was a mixture of phytase, cellulase, xylase, maltase and invertase, and the non-pathogenic microorganism was Aspergillus oryzae.
INDUSTRIAL APPLICABILITY
As explained hereinbefore, the Lactobacillus gasseri BNR17 of the invention has wide growth temperature and pH ranges allowed. And, the strain of the invention not only has excellent acid resistance, bile acid resistance and enteric adsorption capacity but also strong antimicrobial activity against pathogenic microorganisms, in addition to weight gaining inhibitory effect. Therefore, the strain of the invention can be effectively used for the production of fermented milk and other fermented products and be very useful as an additive for animal feed as well.
SEQUENCE LISTING
Sequence listing is attached herewith.

Claims (17)

What is claimed is:
1. A Lactobacillus gasseri BNR17 strain of a biologically pure culture deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.
2. The Lactobacillus gasseri BNR17 strain according to claim 1, wherein the strain contains 16S rRNA sequence represented by SEQ ID NO: 1.
3. A composition containing an effective dose of the Lactobacillus gasseri BNR17 of claim 1.
4. The composition according to claim 3, wherein the composition is selected from the group consisting of food, food additive, animal feed and animal feed additive.
5. The composition according to claim 4, wherein the animal feed additive contains at least one selected from the group consisting of other non-pathogenic microorganisms, enzymes and a mixture thereof.
6. A pharmaceutical composition comprising an effective dose of the Lactobacillus gasseri BNR17 of claim 1.
7. A culture solution of the Lactobacillus gasseri BNR17 of claim 1.
8. A method for inhibiting weight gain comprising administering to a subject an effective dose of the Lactobacillus gasseri BNR17 of claim 1.
9. A composition comprising Lactobacillus gasseri BNR17 strain in an enteric coating, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.
10. The composition of claim 9, which further comprises (a) one or more selected from the group consisting of acacia gum, calcium phosphate, alginate, tragacanth gum, calcium silicate, silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil, and (b) one or more selected from the group consisting of a lactose, dextrose, sucrose, sorbitol, mannitol, starch, gelatin, and water.
11. The composition of claim 9, which is in a form of capsule or tablet.
12. The composition of claim 9, which further comprises one or more additional probiotic microorganism selected from the group consisting of Saccharomyces cerevisiae, Bacillus coagulans, Bacillus licheniformis, Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Enterococcus faecium, Enterococcus faecalis, Lactobacillus acidophilus, Lactobacillus alimentarius, Lactobacillus casei, Lactobacillus curvatus, Lactobacillus delbruckii, Lactobacillus johnsonii, Lactobacillus farciminus, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus sakei, Lactococcus lactis and Pediococcus acidilactici.
13. A dry powder comprising live Lactobacillus gasseri cells and a protectant, wherein the live Lactobacillus gasseri cells are of the Lactobacillus gasseri BNR17 strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP, and wherein the protectant comprises powdered skim milk, whey, and/or sucrose.
14. A method of producing a product, comprising mixing a dry powder of claim 13 with at least one substance selected from the group a diluent, a high-fiber additive, an encapsulant, a lipid, an enzyme and a non-pathogenic microorganism,
wherein the live Lactobacillus gasseri cells are of the Lactobacillus gasseri BNR17 strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP; and
wherein the protectant comprises powdered skim milk, whey, and/or sucrose.
15. A culture comprising a culture medium and Lactobacillus gasseri BNR17, wherein the culture is obtained by culturing the Lactobacillus gasseri BNR17 in a culture medium suitable for Lactobacillus gasseri BNR17;
wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP;
wherein the culture comprises an extracellular polysaccharide produced by the Lactobacillus gasseri BNR17; and
wherein the culturing is carried out for 12-36 hours.
16. The culture of claim 15, wherein the culture medium is an MRS medium supplemented with 2% glucose.
17. A method for inhibiting growth of a pathogenic bacterium in intestine of a subject in need thereof comprising administering Lactobacillus gasseri BNR17 strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP, to the subject, wherein the pathogenic bacterium is selected from the group consisting of E. coli, B. cereus, L. monocytogenes, P. mirabilis, S. aureus, and S. typhimurium.
US15/978,986 2006-08-04 2007-05-14 Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation Active 2028-07-17 USRE48652E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/978,986 USRE48652E1 (en) 2006-08-04 2007-05-14 Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20060073722 2006-08-04
KR10-2006-0073722 2006-08-04
US15/978,986 USRE48652E1 (en) 2006-08-04 2007-05-14 Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
US12/376,368 US8309076B2 (en) 2006-08-04 2007-05-14 Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
PCT/KR2007/002363 WO2008016214A1 (en) 2006-08-04 2007-05-14 Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
US201414537565A 2014-11-10 2014-11-10

Publications (1)

Publication Number Publication Date
USRE48652E1 true USRE48652E1 (en) 2021-07-20

Family

ID=38997371

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/978,986 Active 2028-07-17 USRE48652E1 (en) 2006-08-04 2007-05-14 Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
US12/376,368 Ceased US8309076B2 (en) 2006-08-04 2007-05-14 Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
US14/537,565 Active 2028-07-17 USRE46912E1 (en) 2006-08-04 2007-05-14 Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/376,368 Ceased US8309076B2 (en) 2006-08-04 2007-05-14 Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
US14/537,565 Active 2028-07-17 USRE46912E1 (en) 2006-08-04 2007-05-14 Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation

Country Status (7)

Country Link
US (3) USRE48652E1 (en)
EP (1) EP2046943B1 (en)
JP (1) JP5081242B2 (en)
KR (1) KR101108428B1 (en)
CN (1) CN101541947B (en)
DK (1) DK2046943T3 (en)
WO (1) WO2008016214A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200297786A1 (en) * 2018-04-05 2020-09-24 Hooman Melamed Probiotic Formulation and Method for Weight Loss Treatment

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1973406B1 (en) 2005-12-28 2014-03-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
USRE48652E1 (en) * 2006-08-04 2021-07-20 Bioneer Corporation Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
CA2673120C (en) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation A dry food product containing live probiotic
EP1987726A1 (en) * 2007-05-01 2008-11-05 Friesland Brands B.V. Good tasting food product containing a neutralisation agent for adverse compounds
EE05340B1 (en) * 2008-05-13 2010-08-16 O� Tervisliku Piima Biotehnoloogiate Arenduskeskus Lactobacillus plantarum Tensia DSM 21380 and its use as an antimicrobial and antihypertensive probiotic in the manufacture of a medicament and for the prolongation of food shelf-life and contamination of food
WO2010096550A2 (en) * 2009-02-18 2010-08-26 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
WO2010111565A2 (en) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
SG174958A1 (en) * 2009-03-30 2011-11-28 Meiji Co Ltd Method for culturing lactic acid bacterium and method for producing fermented milk
SG174959A1 (en) * 2009-03-30 2011-11-28 Meiji Co Ltd Method for culturing lactic acid bacterium and method for producing fermented milk
EP2248908A1 (en) * 2009-05-05 2010-11-10 Eurolactis Group S.A. Probiotic microorganisms isolated from donkey milk
CA2763074C (en) 2009-05-26 2021-02-23 Moti Harel Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US20120107291A1 (en) 2009-06-19 2012-05-03 Danisco A/S Bifidobacteria for treating diabetes and related conditions
US20120107450A1 (en) * 2009-06-30 2012-05-03 Chr-Hansen A/S Method for producing a fermented milk product
BG110506A (en) 2009-10-27 2011-05-31 "Селур Вк Холдинг" Еоод New strains of yoghurt bacteria and their combinations for the production of probiotic preparations
ES2639397T3 (en) 2010-01-28 2017-10-26 Advanced Bionutrition Corporation Dry vitreous composition comprising a bioactive material
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
JP5923238B2 (en) * 2010-07-07 2016-05-24 アサヒグループホールディングス株式会社 Vagus nerve activator
AU2011289272B2 (en) 2010-08-13 2015-02-05 Advanced Bionutrition Corporation Dry storage stabilizing composition for biological materials
KR101249824B1 (en) * 2010-12-16 2013-04-03 대상에프앤에프 주식회사 Plant origin lactic acid bacteria Lactobacillus plantarum DSR J1-8 having preventing effect of metabolic syndrome and its use
CN102169034B (en) * 2011-01-24 2012-04-18 吉林大学 Device for quickly measuring torque of loader transmission shaft
JP6002582B2 (en) * 2011-01-25 2016-10-05 株式会社明治 Gastrin production inhibitor and food composition containing the same
GB201102857D0 (en) 2011-02-18 2011-04-06 Danisco Feed additive composition
GB201102865D0 (en) 2011-02-18 2011-04-06 Danisco Feed additive composition
CN103429093A (en) 2011-02-18 2013-12-04 杜邦营养生物科学有限公司 Feed additive composition
EE05721B1 (en) * 2011-02-25 2014-08-15 OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus Isolated microorganism strain L. plantarum MCC1 DSM 23881 and its use
CN102551046B (en) * 2011-12-16 2014-07-16 无限极（中国）有限公司 Natural health composition for weight reduction and application of same
GB201213801D0 (en) 2012-08-03 2012-09-12 Dupont Nutrition Biosci Aps Feed additive composition
KR101444216B1 (en) 2012-11-20 2014-09-26 대한민국 Probiotic Lactobacillus brevis JSB22 Having Extracellular Polysaccharide Producing Actibity
KR101636014B1 (en) * 2014-07-24 2016-07-04 수원대학교산학협력단 Lactobacillus sp. having anti-viral and anti-bacterial activity and use thereof
EA034017B1 (en) * 2014-08-29 2019-12-19 Мухаммед Маджид Methods based on cultivating bacillus coagulans mtcc 5856 in the presence of natural plant fibers
KR102125548B1 (en) 2015-02-10 2020-06-24 주식회사 지니스 Microorganism having Anti-Obesity Ability and Pharmaceutical Composition Containing the same
KR101664310B1 (en) * 2015-02-16 2016-10-10 (주)케비젠 Lactobacillus gasseri CBG-C20 strain producing conjugated linoleic acid and uses thereof
CN108347982A (en) 2015-07-29 2018-07-31 高级生物营养公司 The drying probiotic composition of stabilization for special diet purposes
BE1023757B1 (en) * 2016-06-30 2017-07-12 Yun NV STORAGE OF MICRO-ORGANISMS
WO2018112740A1 (en) * 2016-12-20 2018-06-28 深圳华大基因研究院 Lactobacillus gasseri, culture method therefor and application thereof
WO2018145294A1 (en) 2017-02-10 2018-08-16 Perfect (China) Co., Ltd. Novel probiotics bifidobacteria strains
CN108517347B (en) * 2018-04-12 2020-08-04 江南大学 Bacteroides cellulolysiticus screening culture medium and application thereof
WO2020009893A1 (en) * 2018-07-05 2020-01-09 Dupont Nutrition Biosciences Aps Use of glucosyl transferase to provide improved texture in fermented milk based products
KR102063554B1 (en) 2018-09-12 2020-01-09 (주)성운파마코피아 Lactobacillus gasseri swpm102 which has antifungal activity or antibacterial activity
CN111281894B (en) * 2018-12-07 2022-03-25 深圳华大生命科学研究院 Use and composition of lactobacillus gasseri for preventing and/or treating metabolic diseases
CN109511821A (en) * 2019-01-10 2019-03-26 杨婧芳 A kind of prevention and treatment bird flu feed addictive and preparation method thereof
CN110596227B (en) * 2019-08-08 2021-11-23 河北省食品检验研究院（国家果类及农副加工产品质量监督检验中心、河北省食品安全实验室） Preparation method of time-of-flight mass spectrum ready-to-use type salmonella stanliensis qualitative standard sample
EP4059350A4 (en) * 2019-11-11 2023-12-06 Kabushiki Kaisha Yakult Honsha Method for producing fermented milk containing oligosaccharides
KR102266852B1 (en) * 2019-12-12 2021-06-18 대한민국 Novel bacteriocin-producing Lactobacillus gasseri G2 with antibacterial activity
CN111518724B (en) * 2020-01-19 2021-04-06 河北医科大学 Lactobacillus gasseri HMV18 and secreted protein and application thereof
AU2021224434B2 (en) * 2020-02-17 2024-10-10 Acebiome Inc. Composition for treating climacteric disorder comprising Lactobacillus gasseri BNR17
KR102567790B1 (en) * 2021-01-11 2023-08-17 (주)지에프씨생명과학 Lactobacillus gasseri GFC_1220(GFC_EJR_JOY) for alcohol metabolism enzyme activity and food composition comprising the same as an effective ingredient
CN115039884B (en) * 2021-05-14 2023-11-03 江苏艾兰得营养品有限公司 Lactobacillus rhamnosus with function of inhibiting growth of Proteus mirabilis, and probiotic composition, fermentation liquor and application thereof
CN114409824B (en) * 2022-02-23 2022-11-15 皖南医学院 Mucor exopolysaccharide and preparation method and application thereof
WO2024196040A1 (en) * 2023-03-21 2024-09-26 한국생명공학연구원 Novel lactobacillus sp. strain and use thereof
CN117925484B (en) * 2024-03-19 2024-07-09 山东中科嘉亿生物工程有限公司 Lactobacillus reuteri JYLB-101 for improving sleep apnea, and product and application thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004551A (en) 1991-11-15 1999-12-21 Urex Biotech, Inc. Lactobacillus and skim milk pharmaceutical compositions
US6596530B1 (en) * 1999-06-24 2003-07-22 Meiji Dairies Corporation Strain of Lactobacillus gasseri
WO2004003235A2 (en) 2002-06-28 2004-01-08 Puleva Biotech, S.A. Probiotic strains, a process for the selection of them, compositions thereof, and their use
US20040115179A1 (en) 2002-10-30 2004-06-17 Yu-Ju Liu Acid- and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol
US6808703B2 (en) 2000-05-17 2004-10-26 Bioneer Corporation Lactobacillus KCTC 0774BP and acetobacter KCTC 0773BP for treatment or prevention of obesity and diabetes mellitus
JP2005080636A (en) 2003-09-11 2005-03-31 Kyoritsu Seiyaku Kk Method for producing gassericin a, antibacterial agent, and treating agent of inflammation
US6942857B2 (en) 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus
US7001756B1 (en) 2004-02-19 2006-02-21 Genmont Biotech Inc. Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity
US7115291B1 (en) 1999-08-03 2006-10-03 Kabushiki Kaisha Yakult Honsha Fermented milk drinks and foods and process for producing the same
US7807440B2 (en) * 2004-10-05 2010-10-05 Probi Ab Probiotic Lactobacillus strains for improved vaginal health
USRE46912E1 (en) * 2006-08-04 2018-06-26 Bioneer Corporation Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004551A (en) 1991-11-15 1999-12-21 Urex Biotech, Inc. Lactobacillus and skim milk pharmaceutical compositions
US6596530B1 (en) * 1999-06-24 2003-07-22 Meiji Dairies Corporation Strain of Lactobacillus gasseri
US7115291B1 (en) 1999-08-03 2006-10-03 Kabushiki Kaisha Yakult Honsha Fermented milk drinks and foods and process for producing the same
US6808703B2 (en) 2000-05-17 2004-10-26 Bioneer Corporation Lactobacillus KCTC 0774BP and acetobacter KCTC 0773BP for treatment or prevention of obesity and diabetes mellitus
WO2004003235A2 (en) 2002-06-28 2004-01-08 Puleva Biotech, S.A. Probiotic strains, a process for the selection of them, compositions thereof, and their use
US6942857B2 (en) 2002-08-09 2005-09-13 Bioneer Corporation Microorganisms for preventing and/or treating obesity or diabetes mellitus
US20040115179A1 (en) 2002-10-30 2004-06-17 Yu-Ju Liu Acid- and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol
JP2005080636A (en) 2003-09-11 2005-03-31 Kyoritsu Seiyaku Kk Method for producing gassericin a, antibacterial agent, and treating agent of inflammation
US7001756B1 (en) 2004-02-19 2006-02-21 Genmont Biotech Inc. Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity
US7807440B2 (en) * 2004-10-05 2010-10-05 Probi Ab Probiotic Lactobacillus strains for improved vaginal health
USRE46912E1 (en) * 2006-08-04 2018-06-26 Bioneer Corporation Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
A.C. Majhenic, et al.: "DNA analysis of the genes encoding acidocin LF221 A and acidocin LF221 B, two bacteriocins produced by Lactobacillus gasseri LF221," Appl. Microbiol. Biotechnol., vol. 63, Sep. 18, 2003, pp. 705-714.
Accessions AF243173, AF243144, AF243156, 519171.
Hammami, Cell. Mol. Life Sci. vol. 70: pp. 2947-2967 (Year 2013). *
Jackson et al., 2002, J. of Microbiol. Methods 51:313-321.
Kirjavainen et al., FEMS Immunol. And Med. Micro., 26:131-35, 1999.
Kitazawa. H., International Journal of Food Microbiology 40 (1998) 169-175 (Year: 1998). *
Majhenic, A.G. et al., DNA analysis of the genes encoding acidocin LF221 A and acidocin LF221 B, two bacteriocins produced by Lactobacillus gasseri LF221, Appl. Microbiol. Biotechnol., vol. 63, pp. 705-714. (2004).
Martin et al., J Hum Lact 21(1), 2005 (Year: 2005). *
Mosca et al., Human milk: composition and health benefits, La Pedriatria Medica e Chirurgica, v.39:155, pp. 47-52, 2017.
NCBI GenBank Accession No. AB029612: "Lactobacillus gasseri gassericin T gene region (ORF1, ORF2, ORF3, gatA, gatX, ORF6), complete cds," Oct. 27, 2000, 3 pages.
NCBI GenBank Accession No. AY297947: "Lactobacillus gasseri putative complement factor, acidocin LF221B, and putative immunity protein genes, complete cds; and unknown genes," Nov. 4, 2005, 2 pages.
Pavlova et al 2002, J. Appl. Microbiol. 92 (3), 451-459. *
StrainInfobeta F. Gasser AM 63.
Supplementary European Search Report issued in EP Appln. No. 07 74 6512, dated Aug. 17, 2010, 2 pages.
Usman et al., J. of Dairy Res., 2001:617-624.
Y. Kawai et al.: "Primary Amino Acid and DNA Sequences of Gassericin T, a Lactacin F-Family Bacteriocin Produced by Lactobacillus gasseri SBT2055," in Biosci. biotechnol. Biochem, vol. 64(10), Jun. 6, 2000, pp. 2201-2208.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200297786A1 (en) * 2018-04-05 2020-09-24 Hooman Melamed Probiotic Formulation and Method for Weight Loss Treatment

Also Published As

Publication number Publication date
KR20080110447A (en) 2008-12-18
JP5081242B2 (en) 2012-11-28
EP2046943A4 (en) 2010-09-22
WO2008016214A1 (en) 2008-02-07
CN101541947A (en) 2009-09-23
JP2009545311A (en) 2009-12-24
KR101108428B1 (en) 2012-01-31
EP2046943A1 (en) 2009-04-15
US8309076B2 (en) 2012-11-13
CN101541947B (en) 2013-03-13
DK2046943T3 (en) 2013-09-23
EP2046943B1 (en) 2013-06-19
USRE46912E1 (en) 2018-06-26
US20100203025A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
USRE48652E1 (en) Lactic acid bacteria isolated from mother&#39;s milk with probiotic activity and inhibitory activity against body weight augmentation
US10653730B2 (en) Lactic acid bacterium, drug, food or drink, and feed which contain the lactic acid bacterium
US10597740B2 (en) Bifidobacterium longum CBT BG7 strain for promotion of growth and nutraceutical composition for promotion of growth containing the same
JP2021522867A (en) Lactobacillus paracasei strain and its use
KR101520413B1 (en) Composition for promoting digestion containing medicinal herb and microorganism
KR102024883B1 (en) Lactobacillus Fermentum KBL 375 and Use Thereof
JP2019510520A (en) New bacterial species
EP3255140B1 (en) Lactic acid bacteria, natural immunoactivator and infection preventative/therapeutic derived from said lactic acid bacteria, and food/beverage
EP3135755B1 (en) Bifidobacterium breve cbt br3 strain for promoting growth and functional food composition containing same for promoting growth
US11241463B2 (en) Lactic acid bacterium, drug, food or drink, and feed which contain the lactic acid bacterium
KR20190068026A (en) Lactobacillus plantarum BK-022 or anti-inflammatory composition comprising comprising thereof
US10098916B2 (en) Strains of the genus Lactobacillus and use thereof
JP7369976B2 (en) Lactic acid bacteria, natural immune activators derived from the lactic acid bacteria, infectious disease prevention/treatment drugs, and food and beverages
JPWO2018034203A1 (en) Novel lactic acid bacteria, innate immunity activator containing the novel lactic acid bacteria as an active ingredient, and food and drink containing the novel lactic acid bacteria
KR20220057323A (en) Composition for preventing, alleviating, or treating NAFLD, obesity, or dyslipidemia comprising Lactobacillus mudanjiangensis CKDB001 strain
KR20240102112A (en) Lactobacillus having prophylactic or therapeutic activity for colitis disease and having antibacterial activity against harmful bacteria in the intestine and uses thereof

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 12